Janux Therapeutics Reports Third Quarter 2026 Financial Results and Business Highlights
Business Wire•05/11/2026•16:02 ET
0
Key Highlights
- ➤$945.7 million cash, equivalents and short-term investments supports multiple clinical programs
- ➤First patient dosed in Phase 1 JANX013 plus JANX007 mCRPC combination study
- ➤JANX011 initial healthy-volunteer clinical data scheduled for November 9, 2026 webcast
- ➤JANX007 Phase 1b advances in taxane-naïve and darolutamide combination cohorts
- ➤Q3 net loss $21.6 million versus $24.3 million year over year
Expert Statements
David Campbell, Ph.D., President and Chief Executive Officer of Janux Therapeutics
“During the third quarter, we continued to execute across our clinical portfolio, including dosing the first patient in the Phase 1 study of JANX013 in combination with JANX007”
David Campbell, Ph.D., President and Chief Executive Officer of Janux Therapeutics
“We are also preparing to present initial clinical data from JANX011 on November 9. JANX011 was designed to achieve deep B-cell depletion while limiting cytokine release. The upcoming clinical update will provide an initial look at how this differentiated approach translates into humans.”
Janux Therapeutics Reports Third Quarter 2026 Financial Results and Business Highlights
* Initial clinical data from the Phase 1 healthy-volunteer study of JANX011 to be presented during an investor webcast on November 9, 2026
Get started
Create a free account to read the full story.